TRT and fertility: the conversation that should happen first
Testosterone therapy suppresses sperm production. If children are a possibility, this is the single most important thing to settle before the first dose.
Testosterone therapy is an effective male contraceptive, and that is how it was studied for two decades: the World Health Organization ran multinational trials in the 1990s testing weekly testosterone injections as a reversible method of male birth control. Fertility intentions therefore belong in the first consultation rather than at the three-month review, because the decisions that follow from them are different decisions.
Why treatment suppresses sperm production
Sperm production depends on the testosterone inside the testis rather than on the concentration in the blood, and the two differ by about two orders of magnitude. In a study of 29 healthy men published in the Journal of Clinical Endocrinology & Metabolism, intratesticular testosterone measured approximately 1,234 nmol/L against a serum concentration of around 14.1 nmol/L — roughly 80 to 100 times higher inside the testis. Spermatogenesis, the manufacture of sperm, requires that gradient.
The gradient is maintained by luteinising hormone (LH) from the pituitary, which drives testosterone production in the Leydig cells of the testis. Injected testosterone raises the blood level, the pituitary registers it and switches off LH and follicle-stimulating hormone (FSH), and local production collapses: in that same study, men given testosterone enanthate without supporting treatment saw intratesticular testosterone fall to 72 nmol/L, a 94% reduction. Suppressed FSH compounds it, since FSH acts on the Sertoli cells that support developing sperm. A serum measurement carries no information about the intratesticular concentration, which no routine blood test reaches, so a man on treatment can sit at 900 ng/dL with nothing in the ejaculate.
How completely, and how reliably
In the WHO trials of weekly testosterone enanthate, 65% of men — 157 of 241 — became azoospermic, meaning no sperm in the ejaculate at all, at a mean of around 120 days. Most of the remainder were severely suppressed without reaching zero, which is why the method never came to market as contraception and why it cannot be relied on as one.
Suppression also differs by population. Azoospermia occurred in approximately 91% of Chinese men against around 60% of non-Asian men on identical regimens, and in a pooled analysis of 1,756 men, Caucasian men suppressed below one million per millilitre in up to 80% of cases against up to 90% of East Asian men.
Recovery after stopping
The best recovery data come from an integrated analysis by Liu and colleagues, published in The Lancet in 2006, pooling recovery across 30 studies of healthy men treated in contraceptive trials.
| Sperm concentration | Median time to recovery |
|---|---|
| 3 million/mL | 2.5 months |
| 10 million/mL | 3.0 months |
| 20 million/mL | 3.4 months |
The probability of returning to at least 20 million/mL was 67% by 6 months, 90% by 12 months, 96% by 16 months and 100% by 24 months. The AUA cites essentially the same figures, adding that about 10% of men did not recover until the second year.
The population behind those numbers was healthy young men with normal testosterone, treated for a defined period under supervision, which is not the same as a man who has been on testosterone cypionate for six years. Recovery was faster with shorter treatment duration, higher baseline sperm concentration, shorter-acting preparations and Asian ethnicity.
Two distinctions tend to get lost. A sperm count is a laboratory milestone rather than fertility itself, which also depends on motility, morphology, DNA integrity, a partner's age and timing. And nothing moves quickly once the axis restarts: a cycle of spermatogenesis takes approximately 74 days and new sperm spend a further two to three weeks in epididymal transit, so roughly three months pass before resumed production becomes measurable.
Banking sperm before treatment
Cryopreservation is inexpensive relative to what it protects and stored sperm stays viable for many years. For a man who may want biological children, banking before the first dose converts a risk that is irreversible in a minority into a manageable one, and the sample worth freezing is the one taken before anything has suppressed it.
Preserving fertility during treatment
Human chorionic gonadotropin (hCG) mimics LH and stimulates the Leydig cells directly, maintaining intratesticular testosterone while the pituitary is suppressed. In the dose-ranging study above, hCG restored it dose-dependently in men whose gonadotropins had been suppressed by testosterone: 125 IU every other day brought it to roughly 883 nmol/L, still about 25% below baseline; 250 IU restored it to near baseline at about 1,092 nmol/L; 500 IU took it above baseline at around 1,478 nmol/L.
The clinical evidence is thinner than the mechanism. The most-cited study, by Hsieh and colleagues in the Journal of Urology in 2013, was retrospective and included 26 men on testosterone plus hCG 500 IU every other day. Testosterone rose from 207 to 1,056 ng/dL, no patient became azoospermic, sperm density, motility and volume did not change significantly over more than a year, and nine of the 26 achieved pregnancy. No randomised trial of hCG for fertility preservation during testosterone therapy exists.
A different strategy stimulates a man's own production instead of replacing it, by blocking oestrogen feedback at the pituitary with a selective oestrogen receptor modulator. LH and FSH rise and the intratesticular gradient survives, because the stimulation arrives from above rather than overriding the axis from outside. Clomiphene citrate is used off-label for this, with retrospective series reporting testosterone roughly doubling and sperm parameters maintained, on observational evidence only.
Clomiphene is a mixture of two isomers: enclomiphene, which drives the testosterone increase, and zuclomiphene, which is weakly oestrogenic, has a much longer half-life and is implicated in the visual and mood effects some men report. In phase II randomised trials involving 240 men, enclomiphene raised testosterone to around 450 ng/dL with sperm concentration unchanged from baseline at 16 weeks and oligospermia in fewer than 5%, while men on testosterone gel over the same period saw sperm concentration fall by around 60%, with oligospermia in more than half. It is not FDA-approved: developed as Androxal, it received multiple Complete Response Letters over assay issues, isomer-ratio variability and manufacturing controls, and the required phase III programme was never completed. It remains available only through compounding pharmacies, which are not required to demonstrate the isomer purity the FDA found wanting.
Restoring fertility after testosterone
Most men recover by stopping and waiting, and the figures above are the right baseline for that conversation. Waiting is not always what a man needs, because a partner may be 38, an IVF cycle may be booked, or eighteen months may have passed with nothing in the ejaculate.
The published basis for an active approach is a retrospective series of 49 men who presented with azoospermia or severe oligospermia — under 1 million/mL — while on exogenous testosterone. They were treated with hCG 3,000 IU subcutaneously every other day, with clomiphene, tamoxifen, anastrozole or recombinant FSH added at the clinician's discretion. Forty-seven of the 49 recovered sperm production, at a mean of 4.6 months, with a mean first density of 22.6 million/mL, and outcomes did not differ by testosterone formulation or by which adjunct was chosen.
That series had no untreated comparison group. Since most men recover on withdrawal alone, it cannot show that hCG caused the recovery or even that it accelerated it, and the authors described their paper as an early report of feasibility, using the word "presumed" about the benefit. Set the two literatures side by side and the supportable claim is faster and more predictable rather than possible against impossible: untreated, roughly 90% of men are back to 20 million/mL by twelve months, while the treated series averaged 4.6 months.
Men with genuine deficiency who want children
A man with unambiguous deficiency, real symptoms and a near-term wish for children faces a conflict that no option resolves cleanly. The AUA guideline, published 2018 and reviewed with validity confirmed in 2024, is unambiguous on one branch: testosterone therapy should not be prescribed to men who are currently trying to conceive. It permits clinicians to use aromatase inhibitors, hCG or selective oestrogen receptor modulators in men who want fertility, a permissive statement rather than a directive, reflecting an evidence base too thin to mandate anything.
The realistic options are stimulating the axis rather than replacing it, hCG monotherapy, testosterone with hCG co-administration, banking sperm and then treating, or deferring treatment until the family is complete, which is sometimes right and rarely offered. In our practice these protocols are run individually rather than from a single recipe, because which adjunct is added depends on where the axis is stalled: a man with a suppressed FSH and a normal LH is a different problem from a man with both flat, and monitoring uses semen analysis rather than hormone levels alone, since the hormone is the input and the sperm count the outcome. Which route fits a particular man, and on what timetable, is the substance of an individual assessment at the practice.
Questions patients ask
TRT makes you infertile.
It suppresses sperm production in most men, usually reversibly.
What the evidence showsIn WHO contraceptive trials, 65% of men on weekly testosterone became azoospermic, at a mean of around 120 days, and most of the remainder were severely suppressed. Recovery to at least 20 million sperm/mL occurred in 67% of men by six months and 90% by twelve.
What remains uncertainThose data come from healthy young volunteers treated for a defined period. Recovery after years of clinical therapy is less well characterised.
Bottom lineAssume testosterone will stop sperm production, and plan around that assumption.
Strong
My testosterone level tells me whether my fertility is affected.
It carries no information about it.
What the evidence showsIntratesticular testosterone runs roughly 80 to 100 times higher than serum, and exogenous testosterone reduces it by around 94% while the blood level looks excellent. Sperm production depends on that intratesticular concentration, which no routine blood test measures.
What remains uncertainNothing about the principle.
Bottom lineA good level on treatment is not evidence of intact fertility. Only semen analysis is.
Strong
hCG prevents infertility on TRT.
It helps considerably, and "prevents" overstates the evidence.
What the evidence showshCG maintains intratesticular testosterone dose-dependently in men whose gonadotropins are suppressed, reaching about 1,092 nmol/L at 250 IU every other day against a baseline of around 1,234 nmol/L. In 26 men on testosterone plus hCG 500 IU every other day, none became azoospermic, sperm parameters were maintained beyond a year, and nine achieved pregnancy.
What remains uncertainNo randomised trial exists, optimal dosing is extrapolated from physiology studies, and whether it works equally well in all men is unknown.
Bottom lineThe best available preservation strategy for a man who needs testosterone, resting on 26 retrospective patients.
Moderate
I should freeze sperm before starting TRT.
For a man who may want biological children, yes.
What the evidence showsCryopreserved sperm remains viable for many years, and banking converts a small but real risk of incomplete recovery into a manageable one at modest cost.
What remains uncertainVery little. This is among the least contested recommendations in the field.
Bottom lineBank before the first dose rather than after the first follow-up.
Strong
I have been on testosterone for years, so it is too late.
Usually not, and the timeline is shorter than most men assume.
What the evidence showsIn pooled contraceptive-trial data, about 90% of men recovered a sperm concentration of 20 million/mL within twelve months of stopping and effectively all by twenty-four. In a retrospective series of 49 men azoospermic or severely oligospermic on testosterone, 47 recovered on an hCG-based protocol at a mean of 4.6 months.
What remains uncertainWhether the protocol accelerates recovery or merely accompanies it. That series had no untreated comparison group, and its authors described the benefit as presumed. Longer duration of use and older age are associated with slower recovery.
Bottom lineRecovery is the norm. Where there is a deadline, the protocols are about speed and predictability, not about possibility.
Limited
Ready for testosterone care built on a diagnosis?
The first step is a full endocrine evaluation, not a prescription. We see patients across San Diego County and welcome referrals from other physicians.
Our endocrinologists evaluate low testosterone in La Jolla, La Mesa and Poway: low testosterone care at Diabetes & Endocrine Specialists.


